Target intelligence / Profile preview

Dopamine D2 receptor and Dopamine D3 receptor (D2R (for dopamine D2 receptor), D3R (for dopamine D3 receptor))

Target
D2R (for dopamine D2 receptor), D3R (for dopamine D3 receptor)
Molecular classification
G protein–coupled receptor, Receptor, Seven-transmembrane domain receptor, D2-like dopamine receptor family
01

Overview

Dopamine D2 receptor (D2R) and dopamine D3 receptor (D3R) are closely related members of the D2-like dopamine receptor subfamily within the G protein–coupled receptor (GPCR) superfamily. Both are seven-transmembrane receptors that couple to inhibitory Gi/o proteins, leading to inhibition of adenylyl cyclase and modulation of diverse intracellular signaling pathways[1][5][7]. D2R is the primary molecular target for most antipsychotic drugs and is widely expressed in key brain regions implicated in movement, motivation, and psychosis[3][5]. D3R, while highly homologous to D2R, shows a more restricted distribution in limbic areas and is less abundant; it is a focus of drug discovery efforts for disorders involving reward and addiction[4][6]. These receptors have important roles in modulating neurotransmission, regulating hormonal secretions, and mediating the effects of therapeutic agents and drugs of abuse. Their blockade or modulation underlies both the clinical efficacy and side effects of many psychiatric medications, especially for schizophrenia and related disorders[2][4][7]. Selective targeting of D3R, compared to D2R, is of interest for potential reduction in motor side effects and for treatment of cognitive and negative symptoms[4].

Other names
D2 receptor (D2R)DRD2 (gene/protein symbol for dopamine D2 receptor)D3 receptor (D3R)DRD3 (gene/protein symbol for dopamine D3 receptor)Dopamine receptor D2Dopamine receptor D3
02

Mechanism of action

Antagonism: Many antipsychotics act as antagonists or partial agonists at D2 and D3 receptors, blocking dopamine signaling linked to positive symptoms of psychosis[5][2][4]. Partial agonism: Some drugs modulate dopaminergic tone without full blockade (e.g., aripiprazole as a partial agonist)[2]. Dopamine autoreceptor regulation: Presynaptic D2 receptors regulate dopamine release; antagonists increase dopamine tone[5]. Agonist/antagonist modulation of signaling pathways (Gi/o inhibition of adenylyl cyclase, alteration of intracellular calcium)[7][5].

03

Biological functions

Signal transductionModulation of neurotransmissionRegulation of motor functionCognitive functionEmotional responseRegulation of hormone secretion (e.g., prolactin)Synaptic plasticityAutoregulation of dopamine release
04

Disease associations

SchizophreniaPsychosisAddiction (substance use disorders)Parkinson’s diseaseBipolar disorderDepressionCognitive impairmentOther neuropsychiatric and neurodegenerative diseases
05

Safety considerations

Extrapyramidal symptoms (e.g., parkinsonism, dystonia, akathisia, tardive dyskinesia)Hyperprolactinemia and endocrine side effectsCognitive impairment with non-selective D2 antagonismPotential cardiovascular effects (QT prolongation for some drugs)Metabolic side effects (weight gain, diabetes risk with some antipsychotics)
06

Interacting drugs

Antipsychotics: risperidone, haloperidol, spiperone, eticlopride, clozapine, aripiprazole

3 more in the full profile.

07

Biomarkers

Receptor occupancy in PET imaging as a pharmacodynamic biomarkerProlactin levels (as an indirect marker of D2 receptor blockade)Imaging markers for stratifying response or side effects in psychiatric disorders

Beyond the preview

Go deeper on Dopamine D2 receptor and Dopamine D3 receptor (D2R (for dopamine D2 receptor), D3R (for dopamine D3 receptor)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dopamine D2 receptor and Dopamine D3 receptor (D2R (for dopamine D2 receptor), D3R (for dopamine D3 receptor)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call